OUTLINE: Patients receive gemcitabine hydrochloride IV over 30 minutes and doxorubicin hydrochloride IV over 5-10 minutes on days 1 and 8. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.